Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean Gilham

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Biomedicines|April 30, 2021
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In VitroDean Gilham, Audrey L Smith, Li Fu, et al.
Atherosclerosis|December 1, 2022
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cellsSylwia Wasiak, Laura M Tsujikawa, Emily Daze, et al.
Molecular Pharmacology|October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune DiseaseRavi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.
Translational Neuroscience|January 15, 2024
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation <i>in vitro</i> and in a mouse model of systemic inflammationSylwia Wasiak, Li Fu, Emily Daze, et al.
Clinical Epigenetics|July 14, 2019
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanismLaura M Tsujikawa, Li Fu, Shovon Das, et al.
Plos One|March 14, 2012
Metabolic control by S6 kinases depends on dietary lipidsTamara R Castañeda, William Abplanalp, Sung Hee Um, et al.
Cell|April 3, 2021
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infectionRichard J Mills, Sean J Humphrey, Patrick R J Fortuna, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Biomedicines|April 30, 2021
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In VitroDean Gilham, Audrey L Smith, Li Fu, et al.
Atherosclerosis|December 1, 2022
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cellsSylwia Wasiak, Laura M Tsujikawa, Emily Daze, et al.
Molecular Pharmacology|October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune DiseaseRavi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.
Translational Neuroscience|January 15, 2024
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation <i>in vitro</i> and in a mouse model of systemic inflammationSylwia Wasiak, Li Fu, Emily Daze, et al.
Clinical Epigenetics|July 14, 2019
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanismLaura M Tsujikawa, Li Fu, Shovon Das, et al.
Plos One|March 14, 2012
Metabolic control by S6 kinases depends on dietary lipidsTamara R Castañeda, William Abplanalp, Sung Hee Um, et al.
Cell|April 3, 2021
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infectionRichard J Mills, Sean J Humphrey, Patrick R J Fortuna, et al.
Pageof 3